Are we truly taking advantage of technology?

Cara Livernois | | Health Exec | Cybersecurity

Getting a new device brings everyone excitement—how will my life change with this? Will others notice it? And what can this device do for me?

But, in an age filled with a seemingly endless stream of new products, are we actually taking advantage of the technology around us?

In an article in Forbes, Scott Kramer recounts watching his daughter interact with her new Fitbit. The device has a reputation of helping people achieve fitness goals, but the required attention in monitoring the device at all hours seems to affects us all. It might only be a matter of time before we set the device down and never pick it up again.

Read Kramer’s full article by clicking the link below: 

Are We Using Technology Properly or Being Lazy About It?

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

FBI seeking extradition of Israeli prisoner accused of $500M in ransomware attacks
Data breach at chain of clinics impacts 450K patients
Nebraska becomes first state to sue Change Healthcare over data breach
Christmas ransomware exposed over 300K patient records to dark web
Cryo-frozen tissue manufacturer suffers cyberattack
First surgical device of its kind granted key FDA exemption

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.